Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1811 results
May 2016
-
Media Release
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis Paul Hudson and Bruno Strigini appointed to the… -
Media Release
Novartis renforce la division Pharmaceuticals par la création de deux unités d'affaires, Novartis Pharmaceuticals et Novartis Oncology, et nomme de nouveaux dirigeants à son Comité de direction
Paul Hudson devient CEO de Novartis Pharmaceuticals et Bruno Strigini devient CEO de Novartis Oncology ; David Epstein quitte Novartis Paul Hudson et Bruno Strigini sont nommés au Comité… -
Media Release
Novartis fokussiert ihre Division Pharmaceuticals durch Schaffung der Geschäftseinheiten Novartis Pharmaceuticals und Novartis Oncology und beruft deren Leiter in die Geschäftsleitung von Novartis
Paul Hudson wird zum CEO, Novartis Pharmaceuticals, und Bruno Strigini zum CEO, Novartis Oncology, ernannt; David Epstein wird Novartis verlassen Paul Hudson und Bruno Strigini werden in… -
Featured News
Fighting high blood pressure in Vietnam
The Novartis Foundation is launching a blood pressure management program in Vietnam as part of its larger effort to combat the rise of chronic diseases in urban areas of developing countries.
-
Media Release
Novartis Foundation and partners launch innovative hypertension program in Vietnam
Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the… -
Story From Our Labs
Electrical brainstorms traced to genetic mutations
Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.
-
Media Release
Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations
FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro… -
Story From Our Labs
Eye disease tracked to a glitch in starburst cells
A cellular computing error wreaks havoc on vision.
-
In The News
Novartis Access perspectives: Fighting Africa's future epidemics
An editorial for the World Economic Forum by Harald Nusser, Head Novartis Access & Malaria Initiative
April 2016
-
Media Release
Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors
If approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional… -
Story Discovery
Collaborating to unlock secrets of the microbiome
Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.
-
Media Release
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…